Genprex
Genprex
GNPX
NASDAQ
0.35
USD
0.00%
About
Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The Company’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options.
Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid nanoparticles. The Company’s lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
Using a different gene therapy delivery system, the Company is also developing its preclinical diabetes candidate GPX-002 using the same construct for both Type 1 diabetes and Type 2 diabetes. It conducts preclinical research to explore how REQORSA may be administered in other solid tumors..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 219.4K |
| Three Month Average Volume | 4.0M |
| High Low | |
| Fifty-Two Week High | 22.412 USD |
| Fifty-Two Week Low | 0.5644 USD |
| Fifty-Two Week High Date | 06 Sep 2023 |
| Fifty-Two Week Low Date | 15 Aug 2024 |
| Price and Volume | |
| Current Price | 0.68485 USD |
| Beta | -1 |
| Relative Price Change | |
| Four Week Relative Price Change | -58.71% |
| Thirteen Week Relative Price Change | -79.43% |
| Twenty-Six Week Relative Price Change | -86.10% |
| Fifty-Two Week Relative Price Change | -97.37% |
| Year-to-Date Relative Price Change | -93.71% |
| Price Change | |
| One Day Price Change | 1.99% |
| Thirteen Week Price Change | -77.98% |
| Twenty-Six Week Price Change | -84.71% |
| Five Day Price Change | -4.06% |
| Fifty-Two Week Price Change | -96.71% |
| Year-to-Date Price Change | -92.56% |
| Month-to-Date Price Change | -59.24% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 4.99117 USD |
| Book Value Per Share (Most Recent Quarter) | 1.70031 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 2.89078 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.84018 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -15.65762 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -22.56299 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -16.04129 USD |
| Normalized (Last Fiscal Year) | -22.56299 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -22.56299 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -16.04129 USD |
| Including Extraordinary Items (Last Fiscal Year) | -22.56299 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -16.04129 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 4.53438 USD |
| Cash Per Share (Most Recent Quarter) | 0.96216 USD |
| Cash Flow Per Share (Last Fiscal Year) | -22.55197 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -15.5707 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -12.40917 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -26.53% |
| Tangible Book Value (5 Year) | -12.76% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -7.13% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 51.07% |
| EPS Change (Trailing Twelve Months) | 33.95% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 0 |
| Price to Tangible Book (Most Recent Quarter) | 1 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -2,459,020 |
| Net Debt (Last Fiscal Year) | -6,737,630 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 0 |
| Price to Book (Most Recent Quarter) | 0 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 2 |
| Current Ratio (Most Recent Quarter) | 2 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -24,809,980 |
| Free Cash Flow (Trailing Twelve Months) | -20,824,540 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -172.62% |
| Return on Assets (Trailing Twelve Months) | -232.21% |
| Return on Assets (5 Year) | -92.06% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -207.88% |
| Return on Equity (Trailing Twelve Months) | -318.88% |
| Return on Equity (5 Year) | -98.32% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -207.88% |
| Return on Investment (Trailing Twelve Months) | -318.88% |
| Return on Investment (5 Year) | -98.32% |